MA-BRIGHTCOVE
22.6.2020 05:32:09 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, announced today that BadaBusiness.com , an ed-tech platform founded by Dr. Vivek Bindra, has set two new Guinness World Records for the largest online business and sales lessons streamed, which were powered by Brightcove. The live webinars were joined by BadaBusiness.com’s customers, as well as attendees looking to ‘learn and earn at home’ by exploring the means of upskilling, training, and acquiring new business knowledge. These webinars are a part of Dr. Vivek Bindra’s ‘India Revival Mission,’ which derived from the impact of COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200621005050/en/
The first webinar, titled Largest Online Business Lesson , had a previous record of 12,091 unique attendees, and on April 24, 2020, the stream set a new world record of 18,693 attendees. The second world record was set by BadaBusiness.com on May 31, 2020, when it debuted its Largest Online Sales Lesson webinar with 95,087 attendees. BadaBusiness.com will be hosting the World's Largest Strategy Session on June 27, 2020, to mark International MSME Day .
Brightcove helps organizations in more than 70 countries meet business challenges through its robust, scalable, and intuitive video platform. Powering BadaBusiness.com’s online events is yet another example of how organizations are pushing the boundaries by inspiring, entertaining, and engaging their audiences through video. According to live analytics data captured by Brightcove’s platform, BadaBusiness.com achieved peak traffic of over 2.3 million total video views, over 1.3 million unique viewers, and 345,000 peak concurrent users during the live event on May 31st.
“Our mission is to provide extensive knowledge of practical business strategies and frameworks to enterprises across India so they can grow and strengthen their brand. With video, BadaBusiness.com is able to host online webinars to deliver those important business messages, while also experiencing better engagement with our audiences,” said Dr. Vivek Bindra, Founder of BadaBusiness.com. “Not only is it an accomplishment to simultaneously bring together nearly 100,000 attendees who share similar business goals, but we also broke two Guinness World Records, all thanks to Brightcove’s technology.”
“At Brightcove, we are always working with our customers to pursue unique and innovative use cases of video. BadaBusiness.com’s online events demonstrate how video can offer educational and informative content, while also being one of the best ways to bring people together virtually,” said Charles Chu, Chief Product Officer, Brightcove. “We’re ecstatic that BadaBusiness.com now holds two world records for the largest online streamed events while choosing Brightcove to power those experiences for their audiences.”
About BadaBusiness.com
A technology-enabled training company that provides affordable, available and accessible business training programs to MSME Business Owners, Entrepreneurs and Wantapreneurs in vernacular language, through a combination of online and offline delivery mechanisms. The objective is to empower individual entrepreneurs and small businesses to scale up, by providing them tools and problem-solving support ecosystem.
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200621005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom